Abstract: A process for the separation and purification of hafnium and zirconium.

Abstract: A process in which isotopes of the same element belonging to the alkaline earth metals, transition elements and heavy metals having an atomic mass of less than 209, in particular lanthanide metals, are separated in an aqueous medium by treating an aqueous medium.

Abstract: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.

Abstract: The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, noradrenaline and/or any other neurotransmitter. The proportion by volume of xenon of the mixture ranges between 5 and 45%, and the proportion by volume of nitrous oxide ranges between 10 and 50%, the balance is preferably oxygen.

Abstract: The invention concerns novel diphosphines of formula (I) useful in particular, in their optically active form, as ligands in metal complexes. The invention also concerns their uses an intermediates in the preparation of polymeric insoluble ligands. The invention further concerns the use of said insoluble ligands in the preparation of metal complexes for asymmetric. catalysis.

Abstract: A process for denitrogenation of hydrocarbonated compounds containing basic and/or neutral nitrogenous hydrocarbonated compounds characterized by the fact that the hydrocarbonated compounds are placed in contact with a polymeric material including at least one polymer P obtained from at least one non-styrenic monomer A with at least one polar function generating hydrogen bonds with the nitrogenous hydrocarbonated compounds.

Abstract: The invention concerns the use of at least one gas in combination with at least one active product for manufacturing an inhalable medicament or part of an inhalable medicament intended for the treatment or prevention of pain in humans or animals. The gas is chosen from among helim, oxygen, nitrogen, xenon, hydrogen, carbon monoxide (CO), carbon dioxide (CO2), argon, krypton, nitrogen monoxide (NO), nitrogen protoxide (N2O), carbonated hydrocarbons, fluorocarbons and mixtures of several of these gases. The active product is chosen from among paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steoroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine and morphine mimetics.

Abstract: The invention relates to the use of argon (Ar) gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neuro-transmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.

Abstract: The invention relates to the separation of lanthanides and actinides by nanofiltration complexation. The object of the invention is to satisfy the existing need for a simple, efficient and economical technique for separating lanthanides and actinides. This object is achieved by a process consisting of using ligands of the polyamino acid type, such as EDTA or DTPA, for complexing lanthanides and/or actinides before separating them by nanofiltration. The invention further relates to novel polyamino acid ligands incorporating ligand structures additional to EDTA and DTPA. Application to the production of rare earths or nuclear waste processing, especially to recycling operations carried out on spent nuclear fuels is also discussed.

Abstract: A medicinal composition and method to treat, minimize, or prevent post-ischemic brain cell deterioration that comprises nitrous oxide or a nitrous oxide donor. The method comprises administering the medicinal composition prior to or subsequent to a stroke.

Abstract: The invention concerns a water soluble compound of formula (a) wherein: A represents naphthyl or phenyl; and Ar1 and Ar2 independently represent a saturated or aromatic carbocyclic group; Xa, Xb are independently selected among an amino group, an ammonium group and an amino group modified by a linear polyoxyalkylene chain, provided that at least one of Xa and Xb represents ammonium or modified amino.

Abstract: A process in which isotopes of the same element belonging to the alkaline earth metals, transition elements and heavy metals having an atomic mass of less than 209, in particular lanthanide metals, are separated in an aqueous medium by treating an aqueous medium.

Abstract: The invention concerns an optically active polymer obtainable by free radical or anionic polymerisation of an optically active ethylene monomer with epoxide function bearing at least a chiral centre with a copolymerisable ethylene monomer. An example of such a polymer is an optically active copolymer consisting of two types of repeat units A and B of formula: (A), (B), wherein R0 to R12, X, Y1 and Y2, B, * and n are such as defined in claim 1. Another example is an optically active monomer consisting of two types of repeat units A and C, A being as defined above and C corresponding to formula (C). Said polymers are useful, optionally after the epoxide functions are opened, for immobilising enzymes, as polymeric matrix for chiral chromatography, as polymeric support for solid phase synthesis, as ligand for preparing transition metal complexes in regioselective catalysis or as chiral inducer in regioselective catalyst.

Abstract: Compounds of formula VII are described: 1

Abstract: The invention concerns optically active polymers, obtainable by polymerizing chiral diphosphine having a C2 axis of symmetry, excluding all other symmetry element, with one or several polymerizable monomers, said chiral diphosphine consisting of a chiral body bearing two identical functional groups capable of reacting with said polymerizable monomers.

Abstract: The invention concerns a method for preparing a compound of formula (1) wherein: A represents naphthyl or phenyl optionally substituted; and Ar1, Ar2 independently represent a saturated or aromatic carbocyclic group, optionally substituted.

Abstract: A method for separating at least a benzothiophene compound from a hydrocarbon mixture is disclosed. The method includes contacting the mixture of a fraction obtained therefrom with a reagent including an acceptor complexing agent &pgr;, to obtain a donor-acceptor complex between the acceptor complexing agent and the benzothiophene compound; and separating the complex from the mixture, or from the fraction, to obtain a fraction depleted or purified in the benzothiophene compound.

Abstract: The invention concerns the use of at least one gas in combination with at least one active product for manufacturing an inhalable medicament or part of an inhalable medicament intended for the treatment or prevention of pain in humans or animals. The gas is chosen from among helium, oxygen, nitrogen, xenon, hydrogen, carbon monoxide (CO), carbon dioxide (CO2), argon, krypton, nitrogen monoxide (NO), nitrogen protoxide (N2O), carbonated hydrocarbons, fluorocarbons and mixtures of several of these gases. The active product is chosen from among paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine and morphine mimetics.

Abstract: The invention relates to a process for separating sodium from aqueous effluents resulting from the reprocessing of spent nuclear fuel elements. According to the invention, the effluent (3) is introduced into a tangential filtration module (11), whose membranes are made from polyaramide, sulphonated polysulphone or perfluorinated ionomer, so as to collect a permeate P containing sodium, depleted in radioactive elements and a retentate R enriched in radioactive elements.

Abstract: The invention relates to a process and an installation for the decontamination of radioactive nitric effluents containing strontium and sodium. According to this process, contacting takes place in 1 of the aqueous effluent with an organic phase incorporating a crown ether such as DCH18C6 and a diluent such as CHCl.sub.3, in order to selectively extract the strontium with respect to the sodium, followed by the reextraction of the strontium in an aqueous solution in 3, followed by fixing in 5 on a cation exchange resin. This leads to a high strontium decontamination level with a very high concentration factor.